Teladoc Health, Inc. TDOC R2KR3KPHARMA
Company Overview
Teladoc Health, Inc. provides virtual healthcare services worldwide. It operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical services, specialty medical, chronic condition management, and mental health services, as well as technologies and enterprise telehealth solutions for hospitals and health systems. Its BetterHelp segment operates a mental health platform that provides online counselling and therapy services through websites, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc and BetterHelp brands. It serves employers, health plans, hospitals and health systems, insurance companies, and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in New York, New York.
Why Investors Should Care
Revenue has grown at a 49.7% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.53B (-1.5% YoY); net profit $-200.32M.
- Trailing 12 Months Year-on-year growth — revenue -4.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 49.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 49.74% |
| 1 Year: | -4.00% |
Stock Price Performance
| 1 Year: | -14.78% |
| 6 Months: | +10.26% |
| 3 Months: | -28.84% |
| 1 Month: | +3.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)57.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 49.7% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 34.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TDOC Teladoc Health, Inc. R2KR3KPHARMA | 6.34 | -6.40 | $1.15B | 0.00% | -10.72% | -12.98% | 49.74% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 503.14M | 521.66M | 565.35M | 592.38M | 611.40M | 629.24M | 652.41M | 660.24M | 646.13M | 642.44M | 640.51M | 629.37M | 631.90M | 626.44M | 613.85M | 606.93M |
| Gross Profit | 8.75M | 11.21M | 13.49M | 15.48M | 18.95M | 19.60M | 25.27M | 27.38M | 30.76M | 34.56M | 51.91M | 54.42M | 62.79M | 66.88M | 76.80M | 82.71M | 83.90M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -3.86M | -12.59M | -16.25M | -12.60M | -14.71M | -14.46M | -20.26M | -13.23M | -14.80M | -14.49M | -21.54M | -24.56M | -19.09M | -18.15M | -15.78M | -17.84M | -22.89M | -22.02M | -19.94M | -15.59M | -21.01M | -7.18M | -19.73M | -84.68M | -78.95M | -60.58M | -6.67B | -3.10B | -71.73M | -77.10M | -71.64M | -64.72M | -87.12M | -841.15M | -44.40M | -120.61M | -54.38M | -51.96M | -61.77M | -37.09M |
| Net Income | -4.53M | -12.70M | -17.06M | -13.25M | -15.30M | -14.88M | -29.77M | -14.26M | -15.65M | -15.41M | -31.33M | -44.38M | -23.86M | -25.08M | -23.26M | -24.88M | -30.15M | -29.32M | -20.35M | -19.04M | -29.60M | -25.68M | -35.88M | -199.65M | -133.82M | -84.34M | -6.67B | -3.10B | -73.48M | -69.23M | -65.18M | -57.07M | -81.89M | -837.67M | -33.28M | -93.01M | -32.66M | -49.51M | -63.84M | -38.91M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.31 | -0.86 | -0.53 | -41.58 | -19.22 | -0.45 | -0.42 | -0.40 | -0.35 | -0.49 | -4.92 | -0.19 | -0.53 | -0.19 | -0.28 | -0.36 | -0.21 |
| R&D Expense | 1.96M | 2.91M | 3.20M | 3.94M | 5.22M | 4.83M | 5.87M | 5.89M | 6.51M | 7.54M | 9.96M | 10.45M | 12.90M | 14.35M | 13.58M | 13.54M | 15.99M | 16.66M | 15.75M | 16.25M | 19.26M | 23.03M | 29.96M | 78.01M | 80.76M | 80.25M | 87.41M | 78.70M | 84.59M | 86.98M | 87.31M | 84.29M | 81.39M | 76.75M | 72.38M | 69.96M | 68.78M | 67.57M | 67.86M | 62.86M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.91M | 43.53M | 77.38M | 123.16M | 233.28M | 417.91M | 553.31M | 1.09B | 2.03B | 2.41B | 2.60B | 2.57B | 2.53B |
| Gross Profit | 15.72M | 33.60M | 56.34M | 91.19M | 171.66M | 289.17M | - | - | - | - | - | - | - |
| Operating Income | -5.87M | -15.15M | -55.78M | -62.66M | -75.39M | -70.85M | -80.44M | -506.42M | -265.63M | -13.65B | -248.55M | -1.02B | -262.95M |
| Net Income | -6.02M | -17.04M | -58.02M | -74.22M | -106.78M | -97.08M | -98.86M | -485.14M | -428.79M | -13.66B | -220.37M | -1.00B | -200.32M |
| Diluted EPS | - | - | - | - | - | - | -1.38 | -5.36 | -2.73 | -84.60 | -1.34 | -5.87 | -1.14 |
| R&D Expense | 3.53M | 7.57M | 14.21M | 21.82M | 34.46M | 54.37M | 64.64M | 164.94M | 311.88M | 333.63M | 348.52M | 307.27M | 277.92M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 91.84M | 229.74M | 303.67M | 824.39M | 1.53B | 1.60B | 17.76B | 17.73B | 4.35B | 4.39B | 3.52B | 2.86B |
| Total Equity | -46.53M | -55.45M | -67.53M | 178.56M | 230.87M | 558.90M | 1.01B | 1.01B | 15.88B | 16.05B | 2.31B | 2.33B | 1.49B | 1.39B |
| Cash & Equivalents | 8.69M | 3.21M | 46.44M | 55.07M | 50.02M | 42.82M | 423.99M | 514.35M | 733.32M | 893.48M | 918.18M | 1.12B | 1.30B | 781.08M |
| Long Term Debt | - | - | 25.04M | 25.23M | 42.42M | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | 2.07B | 2.03B | 1.47B |
| Current Liabilities | - | - | 10.32M | 17.99M | 21.07M | 40.33M | 62.44M | 90.18M | 332.65M | 331.01M | 399.77M | 420.62M | 941.53M | 404.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -47.18M | -51.88M | -34.44M | -4.86M | 29.87M | -53.51M | 193.99M | 189.29M | 350.02M | 293.68M | 294.36M |
| Investing Cash Flow | - | - | -108.20M | 26.15M | -448.38M | -257.50M | 25.01M | -590.98M | -72.98M | -167.74M | -156.35M | -124.05M | -266.00M |
| Financing Cash Flow | - | - | 164.01M | 20.68M | 475.43M | 645.61M | 35.09M | 859.14M | 40.95M | 6.50M | 10.85M | 8.31M | -551.65M |
| Capital Expenditure | -204.00K | -1.07M | -6.28M | -2.11M | -2.63M | -4.01M | -3.51M | -4.02M | -8.53M | -16.48M | -11.46M | -10.79M | -8.89M |
| Free Cash Flow | - | - | -53.46M | -53.98M | -37.07M | -8.87M | 26.36M | -57.53M | 185.46M | 172.81M | 338.56M | 282.89M | 285.46M |
| Share Buybacks | 71.00K | 368.00K | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 79.0% | 77.2% | 72.8% | 74.0% | 73.6% | 69.2% | - | - | - | - | - | - | - |
| Operating Margin % | -29.5% | -34.8% | -72.1% | -50.9% | -32.3% | -17.0% | -14.5% | -46.3% | -13.1% | -567.3% | -9.6% | -39.7% | -10.4% |
| Net Margin % | -30.2% | -39.1% | -75.0% | -60.3% | -45.8% | -23.2% | -17.9% | -44.3% | -21.1% | -567.5% | -8.5% | -39.0% | -7.9% |
| ROE % | 10.9% | 25.2% | -32.5% | -32.1% | -19.1% | -9.6% | -9.7% | -3.1% | -2.7% | -591.9% | -9.5% | -67.1% | -14.5% |
| ROCE % | - | -18.6% | -26.3% | -22.2% | -9.6% | -4.8% | -5.3% | -2.9% | -1.5% | -346.0% | -6.3% | -39.6% | -10.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.93% | 16.22M | $93.61M |
| 2 | Vanguard Portfolio Management LLC | 6.98% | 12.69M | $73.20M |
| 3 | Point72 Asset Management, L.P. | 4.54% | 8.24M | $47.54M |
| 4 | Renaissance Technologies, LLC | 4.44% | 8.07M | $46.58M |
| 5 | Voss Capital, LP | 4.43% | 8.05M | $46.43M |
| 6 | Vanguard Capital Management LLC | 4.38% | 7.96M | $45.90M |
| 7 | Dimensional Fund Advisors LP | 4.06% | 7.37M | $42.53M |
| 8 | State Street Corporation | 2.73% | 4.96M | $28.63M |
| 9 | American Century Companies Inc | 2.69% | 4.89M | $28.24M |
| 10 | Allianz Asset Management GmbH | 2.57% | 4.67M | $26.93M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TDOC
TDOC Apr 2027 8.000 put (TDOC270416P00008000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE9OVmd4SHNua1EzR1ZCS3RHMExQbTlhdDRKVTFzX3A4c244UDNjbThjTWQ3bmdGRS04R2xWYTNZUWxwU2docUxKbTlEcXhWOThKTVBUTm8zc2loWUZhUlFMZlMzOWVaUQ?oc=5" target="_blank">TDOC Apr 2027 8.000 put (TDOC…
TDOC Apr 2027 8.000 put (TDOC270416P00008000) stock historical prices and data - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE5IZVp0Wm5CMzNmSmNScnlrY2hRbHNRRDJOa1A5aV9vTDE3TkxJRkNxdHpGZGNKb3N4QjlPS2FLNVFNZXI1QWhvc3JvNi1URnhzb0JSREJXUnVHYXFjUVo0VG5LUlRiaVprdmtOc2FvT1Y?oc=5" target="_blank">TDOC Apr 2027 8.…
TDOC Oct 2026 7.500 call (TDOC261023C00007500) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE1zejF3TUd2SFBYMUs0VURwWHBHTk81M2FYVjh3WlloQnFXMXd6U0VRcld0TFVsWnQ5R0FuWkR2amRJdUx1d2pOVkMyRDR0TGVuOGFPSnNhNzd1Wlp2bDF0eTB1TC1IUQ?oc=5" target="_blank">TDOC Oct 2026 7.500 call (TDO…
Teladoc (TDOC) Outperforms Broader Market: What You Need to Know - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNT3ppMVdmR2xqa0puTDRNb3lPZEUzd1cwbE9hX19Rcks2Sk52Rm1QSnJqZVNUcDFhcGlQdXpZZlhDOUI1Rk84YUpqTDNNTnJHUndPZy1BRmc2WkFKemd4cms1Y0VMZEhlclFfVTVxc3h0YmNfb3ZmMU5zREZiTmh1MXJWVGJiWTRoQVc2X2…
TDOC Oct 2026 11.000 put (TDOC261023P00011000) stock historical prices and data - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE9YRUJsTU5NSVV6ckdWLWFvWkpka25wWnlZM2ZwUmdmYU95T0doWmRScTdjbDQySndjQmpzdE1adHRpNFRPeU9IM0JrWjJDUVlWMG90Yk5fdjRUYVRNcW00TmVNeWdTQXRQblduUEhrOGU?oc=5" target="_blank">TDOC Oct 2026 11…
TDOC Oct 2026 10.500 put (TDOC261023P00010500) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE1KOGxma2FHUlJ2MGxDZ1otSWhSMjRCSFZoS2J4akRIS2g5cDd6Vi1lVmRPa2k0T1dsYXJqRTAxSzVTeWQyV3k1VlpJY1k0R0N6ZGhMNGp1eVhGOU1EekxKZGVJdkl2UQ?oc=5" target="_blank">TDOC Oct 2026 10.500 put (TDO…
TDOC — Frequently Asked Questions
What is the current share price of Teladoc Health, Inc. (TDOC)?
As of 2026-10-23 16:27 PDT, Teladoc Health, Inc. (TDOC) trades at $6.34 on NYSE. Its 52-week range is $4.47 to $9.72.
What is the market capitalisation of TDOC?
Teladoc Health, Inc. (TDOC) has a market capitalisation of $1.15B on NYSE.
What is the P/E ratio of TDOC?
TDOC trades at a trailing price-to-earnings (P/E) ratio of -6.40. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.87.
What is the return on equity (ROE) of TDOC?
TDOC has a return on equity (ROE) of -12.98%. Its return on capital employed (ROCE) is -10.72%.
Is TDOC a good stock to buy?
This page provides a data-driven analysis of Teladoc Health, Inc. (TDOC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.